Abstract
Purpose
To investigate the outcome of mitomycin C (MMC)-augmented trabeculectomy with subconjunctival bevacizumab in the management of Fuchs heterochromic iridocyclitis (FHI)-related glaucoma in 1-year follow-up period.
Methods
This retrospective study included 50 eyes with FHI-related glaucoma those had underwent initial trabeculectomy with MMC (0.2 mg/ml—3 min). Thirty-one of them had single-dose bevacizumab injection (1.25 mg/0.05 ml) into the bleb area just at the end of the surgery, while 19 eyes did not have. The intraocular pressure (IOP) and the mean number of anti-glaucomatous medications were evaluated. The IOP value ≤ 21 mmHg was defined as complete or qualified surgical success in terms of using medical anti-glaucomatous treatment. Bleb height and vascularity were evaluated with Indiana bleb grading system. Paired sample t test, t test, Chi-square and Kolmogorov–Smirnov tests were used for statistical analysis.
Results
The preoperative IOP values of bevacizumab and without bevacizumab groups were 32.8 ± 4.5 mmHg and 32.8 ± 4.5 mmHg, respectively, and they decreased to 17.5 ± 4.6 mmHg and 17 ± 5.2 mmHg at the final visit (p < 0.001 for all values). There were no significant differences in postoperative IOP and the number of medications between the groups at the final visit. In bevacizumab group, complete success was achieved in 100% within the third month but decreased to 22.5% (complete) and 74.1% (qualified) at the first year. In the other group (without bevacizumab group), complete success was achieved in 94.7% within the third month but decreased to 15.8% (complete) and 84.2% (qualified) at the first year.
Conclusion
Initial trabeculectomy with MMC and subconjunctival bevacizumab injection was found to have lower rates of complete success with relatively acceptable qualified success rates in the management of FHI-related glaucoma. Subconjunctival bevacizumab was not found to have additional effect to improve the surgical success.
Similar content being viewed by others
References
Siddique SS, Suelves AM, Baheti U, Foster CS (2013) Glaucoma and uveitis. Surv Ophthalmol 58:1–10
Al Rubaie K, Al Dhahri H, Al Fawaz A et al (2016) Incidence and risk factors for developing glaucoma among patients with uveitis in a university-based tertiary referral center in Riyadh, Saudi Arabia. Ocul Immunol Inflamm 24:571–578
Tugal-Tutkun I, Güney-Tefekli E, Kamaci-Duman F, Corum I (2009) A cross-sectional and longitudinal study of Fuchs uveitis syndrome in Turkish patients. Am J Ophthalmol 148:510–515
Nalçacıoğlu P, Çakar Özdal P, Şimşek M (2016) Clinical characteristics of Fuchs’ uveitis syndrome. Turk J Ophthalmol 46:52–57
Norrsell K, Sjödell L (2008) Fuchs’ heterochromic uveitis: a longitudinal clinical study. Acta Ophthalmol 86:58–64
Toniolo JT, Hall AJ, Smith JG, Levy J, Lim LL (2017) Risk factors for glaucoma in a cohort of patients with Fuchs heterochromic iridocyclitis. Ocul Immunol Inflamm 25(6):753–759
Hwang DK, Chou YJ, Pu CY, Chou P (2015) Risk factors for developing glaucoma among patients with uveitis: a nation wide study in Taiwan. J Glaucoma 24:219–224
Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser-Bell S (2018) Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev 18(4):CD011599. https://doi.org/10.1002/14651858.cd011599.pub2
Ashraf M, Banaee T, Silva FQ, Singh RP (2018) Switching anti-vascular endothelial growth factors in refractory neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 49:166–170
Kaushik J, Parihar JK, Jain VK et al (2017) Efficacy of bevacizumab compared to mitomycin C modulated trabeculectomy in primary open angle glaucoma: a one-year prospective randomized controlled study. Curr Eye Res 42:217–224
Vahedian Z, Mafi M, Fakhraie G et al (2017) Short- term results of trabeculectomy using adjunctive intracameral bevacizumab versus mitomycin C: a randomized controlled trial. J Glaucoma 26:829–834
Elgin U, Sen E, Çolak S, Yilmazbas P (2019) Initial trabeculectomy with 5-fluorouracil with or without subconjunctival bevacizumab in the management of pseudoexfoliation glaucoma. Int Ophthalmol 39(6):1211–1217
De Fendi LI, Arruda GV, Scott IU, Paula JS (2013) Mitomycin C versus 5-fluorouracil as an adjunctive treatment for trabeculectomy: a meta-analysis of randomized clinical trials. Clin Exp Ophthalmol 41:798–806
Chawla A, Mercieca K, Fenerty C, Jones NP (2013) Outcomes and complications of trabeculectomy enhanced with 5-fluorouracil in adults with glaucoma secondary to uveitis. J Glaucoma 22:663–666
Almobarak FA, Alharbi AH, Morales J, Aljadaan I (2018) The influence of mitomycin C concentration on the outcome of trabeculectomy in uveitic glaucoma. Int Ophthalmol 38(6):2371–2379
Almobarak FA, Alharbi AH, Morales J, Aljadaan I (2016) Outcomes of trabeculectomy with mitomycin-C in uveitis associated with Vogt–Koyanagi–Harada Disease. J Glaucoma 25:528–532
Komae K, Takamoto M, Tanaka R et al (2017) Initial trabeculectomy with mitomycin-C for secondary glaucoma-associated with Uveitis in Behçet disease patients. J Glaucoma 26:603–607
You YA, Wu Y, Hu S (2013) Surgical management of secondary glaucoma in Fuchs’ heterochromic iridocyclitis. Graefes Arch Clin Exp Ophthalmol 251:1785–1790
Ozgonul C, Mumcuoglu T, Gunal A (2014) The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Curr Eye Res 39:451–459
Tai TY, Moster MR, Pro MJ, Myers JS, Katz LJ (2015) Needle bleb revision with bevacizumab and mitomycin C compared with mitomycin C alone for failing filtration blebs. J Glaucoma 24:311–315
Simsek T, Cankaya AB, Elgin U (2012) Comparison of needle revision with subconjunctival bevacizumab and 5- fluorouracil injection of failed trabeculectomy blebs. J Ocul Pharmacol Ther 28:542–546
Bettis DI, Morshedi RG, Chaya C, Goldsmith J, Crandall A, Zabriskie N (2015) Trabeculectomy with mitomycin C or Ahmed valve implantation in eyes with uveitic glaucoma. J Glaucoma 24:591–599
Funding
None of the authors received any financial support or funds and have no financial interests.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
Our presentation was approved by Ethics Committee of Numune Training and Research Hospital.
Informed consent
Written informed consent was taken from the participants.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Elgin, U., Sen, E., Ozdemir, K. et al. The outcome of initial mitomycin C-augmented trabeculectomy with subconjunctival bevacizumab in the management of secondary glaucoma associated with Fuchs heterochromic iridocyclitis. Int Ophthalmol 40, 795–802 (2020). https://doi.org/10.1007/s10792-019-01240-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-019-01240-3